PIQ (ASX) Ann: Study shows diabetes drug improves PromarkerD risk scores

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Hi Owl, Sincere thanks for taking the time to provide a very thorough response to my query. Your insight and knowledge of PIQ is of great benefit to many to less experienced investors in this area.

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

No.	Vol.	Price($)
2	12480	88.0¢

No.

Vol.

Price($)

12480

88.0¢

Price($)	Vol.	No.
89.5¢	58833	1

Price($)

Vol.

No.

89.5¢

58833

No.	Vol.	Price($)
2	12480	0.880
5	162796	0.875
2	36780	0.870
2	4557	0.865
1	600	0.860

No.

Vol.

Price($)

12480

0.880

162796

0.875

36780

0.870

4557

0.865

600

0.860

Price($)	Vol.	No.
0.895	58833	1
0.900	5000	1
0.910	75000	2
0.920	10000	1
0.930	10000	1

Price($)

Vol.

No.

0.895

58833

0.900

5000

0.910

75000

0.920

10000

0.930

10000

(20min delay)
Last 89.5¢		Change 0.010(1.13%)		Mkt cap ! $117.1M

Open	High	Low	Value	Volume
90.5¢	91.5¢	88.0¢	$192.2K	215.3K

Cultural heritage agreement puts Walford Creek exploration back on the map

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Cultural heritage agreement puts Walford Creek exploration back on the map

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News